Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 20/20 | 0.94 |
| ▸ | LCK | P06239 | 1/20 | 0.81 |
| ▸ | CSF1R | P07333 | 1/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.81 |
| ▸ | FLT3 | P36888 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22918774 | 0.97 | KIT (1.00) | KITLCKCSF1RPDGFRBPDGFRA | |
| SCHEMBL22918985 | 0.93 | KIT (0.92) | KITLCKCSF1RPDGFRBPDGFRA | |
| SCHEMBL29614257 | 0.93 | KIT (0.92) | KITLCKCSF1RPDGFRBPDGFRA | |
| SCHEMBL22919087 | 0.93 | KIT (0.86) | KITLCKCSF1RPDGFRBPDGFRA | |
| SCHEMBL22919088 | 0.92 | KIT (0.85) | KITLCKCSF1RPDGFRBPDGFRA | |
| SCHEMBL29615492 | 0.91 | KIT (0.86) | KITLCKCSF1RPDGFRBPDGFRA | |
| SCHEMBL29615574 | 0.91 | KIT (1.00) | KITLCKCSF1RPDGFRBPDGFRA | |
| SCHEMBL22919072 | 0.91 | KIT (0.86) | KITLCKCSF1RPDGFRBPDGFRA | |
| SCHEMBL22918958 | 0.90 | KIT (1.00) | KITLCKCSF1RPDGFRBPDGFRA | |
| SCHEMBL22919069 | 0.90 | KIT (0.85) | KITLCKCSF1RPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114174293-A | 4- (imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives | 默克专利股份公司 | 2022-03-11 | — | — | CN | claimed |
| US-20260109697-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2026-04-23 | — | — | US | disclosed |
| US-20220267320-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-08-25 | — | — | US | disclosed |
| EP-4003992-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL) -PYRIMIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2022-06-01 | — | — | EP | disclosed |
| CN-114174293-A | 4- (imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives | 默克专利股份公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021013864-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL) -PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109697-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | CHUK, CNKSR1, KIT | KIT 3/4885LCK 517/4885CSF1R 1067/4885 |
| US-20220267320-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | NCOA3, NCOR1, NCOA4 | KIT 273/4885LCK 937/4885CSF1R 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.